Skip to main content

PRE-ACT: Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification

Objective

Radiotherapy is a widely used cancer treatment, however some patients suffer side effects. In breast cancer, side effects can include breast atrophy, arm lymphedema, and heart damage. Some factors that increase risk for side effects are known, but current approaches do not use all available complex imaging and genomics data. The time is now ripe to leverage the huge potential of AI towards prediction of side effects. This project will use rich datasets from three patient cohorts to design and implement an AI tool that predicts the risk of side effects, including arm lymphedema in breast cancer patients and provides an easily understood explanation to support shared decision-making between the patient and physician.
The PRE-ACT consortium combines the expertise in computing (MDW, AUEB-RC), AI (HES-SO, CENTAI), radiation oncology (MAASTRO, UNICANCER), medical physics (THERA), genetics (ULEIC), psychology (CNR) and health economics (UM) that is necessary to tackle this problem.
The project will integrate data from the three cohorts and build AI predictive models with built-in explainability for each of the key side effects of breast cancer radiotherapy. These AI models will be incorporated into an existing commercial radiotherapy software platform to create a world-leading product. The extended platform will be validated in a clinical trial to support treatment decisions regarding the irradiation of lymph nodes. The trial will adopt an innovative design in which the patients and medical team in the test arm will receive the risk prediction, but those in the control arm will not. A communication package built with a co-design methodology will ensure that AI outcomes are tailored to stakeholders effectively. The trial will evaluate whether using the AI platform changed the arm lymphedema rate and impacted treatment decisions and quality-of-life. Generalizability of the AI models for other types of cancer will be sought through transfer learning techniques.

Coordinator

ATHENS UNIVERSITY OF ECONOMICS AND BUSINESS - RESEARCH CENTER
Net EU contribution
€ 637 243,75
Address
Kefallinias Street 46
11251 Athens
Greece

See on map

Region
Κεντρικός Τομέας Αθηνών Aττική Αττική
Activity type
Higher or Secondary Education Establishments
Other funding
€ 637 243,75

Participants (7)

UNIVERSITEIT MAASTRICHT
Netherlands
Net EU contribution
€ 422 765,00
Address
Minderbroedersberg 4
6200 MD Maastricht

See on map

Region
Limburg (NL) Zuid-Limburg
Activity type
Higher or Secondary Education Establishments
Other funding
€ 422 765,00
ISTITUTO PER L'INTERSCAMBIO SCIENTIFICO

Participation ended

Italy
Net EU contribution
€ 0,00
Other funding
€ 0,00
CONSIGLIO NAZIONALE DELLE RICERCHE
Italy
Net EU contribution
€ 504 166,00
Address
Piazzale Aldo Moro 7
00185 Roma

See on map

Region
Centro (IT) Lazio Roma
Activity type
Research Organisations
Other funding
€ 504 166,00
UNICANCER
France
Net EU contribution
€ 1 736 624,00
Address
101 Rue De Tolbiac
75013 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 1 736 624,00
STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC
Netherlands
Net EU contribution
€ 437 500,00
Address
Dr. Tanslaan 12
6229 ET Maastricht

See on map

Region
Limburg (NL) Zuid-Limburg
Activity type
Research Organisations
Other funding
€ 437 500,00
MEDICAL DATA WORKS BV
Netherlands
Net EU contribution
€ 318 191,00
Address
Dr Tanslaan 12
6229 ET Maastricht

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Limburg (NL) Zuid-Limburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 318 191,00
CENTAI INSTITUTE SPA
Italy
Net EU contribution
€ 535 625,00
Address
Corso Inghilterra 3
10138 Torino

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Nord-Ovest Piemonte Torino
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 535 625,00

Partners (4)

HAUTE ECOLE SPECIALISEE DE SUISSE OCCIDENTALE
Switzerland
Net EU contribution
€ 0,00
Address
Route De Moutier 14
2800 Delemont

See on map

Region
Schweiz/Suisse/Svizzera Espace Mittelland Jura
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
UNIVERSITY OF LEICESTER
United Kingdom
Net EU contribution
€ 0,00
Address
University Road
LE1 7RH Leicester

See on map

Region
East Midlands (England) Leicestershire, Rutland and Northamptonshire Leicester
Activity type
Higher or Secondary Education Establishments
Other funding
No data
MIRADA MEDICAL LTD

Participation ended

United Kingdom
Net EU contribution
€ 0,00
Address
New Barclay House 234 Botley Road
OX2 0HP Oxford
SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
No data
THERAPANACEA
France
Net EU contribution
€ 0,00
Address
24 Rue Du Faubourg Saint-jacques
75014 Paris

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00